Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SK-1403 Long-term Treatment in Secondary Hyperparathyroidism
NCT03626948Phase 3Completed
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
- Start
- Sep 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of upacicalcet in secondary hyperparathyroidism (SHPT), sponsored by Sanwa Kagaku Kenkyusho Co., Ltd. Primary endpoint: Number of participants with adverse events or adverse drug reactions at 52 weeks. Started Sep 2018; status: completed.
02
Drugs
upacicalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT03626948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03626948.